Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
MOMA Therapeutics
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06545942CT.gov Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06065059CT.gov Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | — | Terminated | — | — | — |
NCT06078787CT.gov Olaparib in PALB2 Advanced Pancreatic Cancer | — | Recruiting | — | — | — |
NCT05411094CT.gov Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer | — | Suspended | — | — | — |
NCT05238831CT.gov SMMART Adaptive Clinical Treatment (ACT) Trial | — | Withdrawn | — | — | — |
NCT05659914CT.gov Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations | — | Active Not Recruiting | — | — | — |
NCT05252390CT.gov NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04753879CT.gov Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | — | Active Not Recruiting | — | — | — |
NCT04548752CT.gov Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | — | Active Not Recruiting | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
Show 4 more trialsShow fewer
NCT04005690CT.gov Targeted Pathway Inhibition in Patients With Pancreatic Cancer | — | Recruiting | — | — | — |
NCT03682289CT.gov Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02677038CT.gov Olaparib in Treating Patients With Stage IV Pancreatic Cancer | — | Completed | — | — | — |
NCT02498613CT.gov A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Pancreatic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Olaparib (this asset) | MOMA Therapeutics | P2 | BB · 70 |
| Immunoglobulin G1, Anti-(Humanized Mouse Monoclonal Hr3 .Beta.1 Chain Anti-Human Epidermal Growth Factor Receptor), Disulfide With Humanized Mouse Monoclonal Hr3 .Kappa.-Chain, Dimer | Chinese PLA General Hospital | P4 | BBB |
| Metformin | State University of New York - Downstate Medical Center | P2 | BBB |
| Fluorouracilum | Jonsson Comprehensive Cancer Center | P4 | BBB |
| Irinotecan | Jonsson Comprehensive Cancer Center | P3 | BB |
| Oxaliplatin | Jonsson Comprehensive Cancer Center | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | Jonsson Comprehensive Cancer Center | P2/3 | BB |
| Tunlametinib | Chinese PLA General Hospital | P4 | BB |
| Dexmedetomidine | Uppsala University Hospital | P4 | BB |
+42 more in the Malignant Pancreatic Neoplasm cohort
Other indications for Olaparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 73 |
| Fallopian Tube Serous Adenocarcinoma | — | P3 | BBB · 72 |
| Ovarian Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Immunoglobulin G1, Anti-(Humanized Mouse Monoclonal Hr3 .Beta.1 Chain Anti-Human Epidermal Growth Factor Receptor), Disulfide With Humanized Mouse Monoclonal Hr3 .Kappa.-Chain, DimerChinese PLA General HospitalBBB
- MetforminState University of New York - Downstate Medical CenterBBB
- FluorouracilumJonsson Comprehensive Cancer CenterBBB
- IrinotecanJonsson Comprehensive Cancer CenterBB
- OxaliplatinJonsson Comprehensive Cancer CenterBB
Citation
Floatz Terminal. Olaparib in Malignant Pancreatic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/olaparib-malignant-pancreatic-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →